Innate Pharma (IPH) Q4 2025 earnings summary

Executive summary

• Advanced three priority clinical assets—lacutamab, IPH4502, and monalizumab—with significant late-stage clinical and regulatory milestones, including FDA Breakthrough Therapy Designation for lacutamab and ongoing phase III trials.

• Workforce restructuring and strategic pipeline prioritization implemented to streamline operations and optimize capital allocation.

• Ongoing negotiations for non-dilutive financing and partnerships to support late-stage trials and commercialization.

Financial highlights

• Revenue and other income for 2025 totaled €9.0 million, down 55% from €20.1 million in 2024, mainly due to lower collaboration and licensing revenue.

• Operating expenses decreased 12% to €63.0 million, with R&D expenses at €43.6 million (69–73% of total), down 16% year-over-year.

• Cash, cash equivalents, and financial assets stood at €44.8 million at year-end 2025, down from €91.1 million in 2024, providing funding visibility through Q3 2026.

• Net loss for 2025 was €49.2 million, nearly flat versus €49.5 million in 2024.

• Net financial income rose to €4.8 million, mainly from favorable foreign exchange impacts.

Outlook and guidance

• Cash runway extends through Q3 2026, but current cash is not sufficient for 12 months from financial statement issuance, raising substantial doubt about going concern without new funding.

• Multiple non-dilutive financing options, including pharma partnerships and royalty structures, are under negotiation to support future operations and clinical trial initiations.

• Key late-stage trials planned: TELLOMAK 3 phase III for lacutamab in CTCL (H2 2026), PACIFIC-9 phase III for monalizumab in NSCLC (data readout H2 2026), and IPH4502 phase I expansion.